Y-mabs therapeutics says it received e-mail notification from fda on oct. 31

Y-mabs therapeutics, inc - on october 31, received e-mail notification from fda.y-mabs therapeutics inc - e-mail notification from fda notified that pre-bla meeting with fda has now been converted to a general guidance meeting.y-mabs therapeutics, inc - fda did not indicate a reason for change to general guidance meet.y-mabs therapeutics inc - expect rolling bla submission for omburtamab will not begin until after a new pre-bla meeting has been scheduled.y-mabs therapeutics, inc - pre-bla meeting could still take place in 2019, or q1 fy2020.
YMAB Ratings Summary
YMAB Quant Ranking